Details for New Drug Application (NDA): 206133
✉ Email this page to a colleague
The generic ingredient in EVEROLIMUS is everolimus. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the everolimus profile page.
Summary for 206133
Tradename: | EVEROLIMUS |
Applicant: | Hikma |
Ingredient: | everolimus |
Patents: | 0 |
Pharmacology for NDA: 206133
Mechanism of Action | Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors Protein Kinase Inhibitors mTOR Inhibitors |
Physiological Effect | Decreased Immunologic Activity |
Medical Subject Heading (MeSH) Categories for 206133
Suppliers and Packaging for NDA: 206133
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
EVEROLIMUS | everolimus | TABLET;ORAL | 206133 | ANDA | Hikma Pharmaceuticals USA Inc. | 0054-0470 | 0054-0470-21 | 60 TABLET in 1 BOTTLE (0054-0470-21) |
EVEROLIMUS | everolimus | TABLET;ORAL | 206133 | ANDA | Hikma Pharmaceuticals USA Inc. | 0054-0471 | 0054-0471-21 | 60 TABLET in 1 BOTTLE (0054-0471-21) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.25MG | ||||
Approval Date: | Apr 12, 2018 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.5MG | ||||
Approval Date: | Apr 12, 2018 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.75MG | ||||
Approval Date: | Apr 12, 2018 | TE: | AB | RLD: | No |
Complete Access Available with Subscription